Doxy PEP & STI Resistance: What You Need to Know
Gonorrhea Treatment Faces Growing Resistance, Experts Warn Doxycycline’s Effectiveness May Be Fleeting
Table of Contents
Gonorrhea, a sexually transmitted infection (STI), is exhibiting increasing resistance to current treatments, raising concerns among public health officials. A recent study highlights the diminishing effectiveness of doxycycline post-exposure prophylaxis (doxy PEP), a practice gaining traction among those at risk. While new treatments are in progress, history suggests these too may eventually succumb to resistance, underscoring the urgent need for continued surveillance and, ultimately, a vaccine.
The Rise of Gonorrhea Resistance and the role of Doxy PEP
For decades, gonorrhea has demonstrated a remarkable ability to evolve and overcome antibiotic defenses. What once responded to penicillin now requires increasingly complex treatment regimens. Currently, the recommended treatment involves a combination of ceftriaxone and azithromycin. Though,resistance to azithromycin is widespread,and concerningly,resistance to ceftriaxone is on the rise.
Enter doxycycline PEP. This involves taking a single dose of the antibiotic doxycycline after potential exposure to gonorrhea to prevent infection. It’s become popular, particularly among men who have sex with men, as a preventative measure, even without formal public health endorsement. The recent study, led by Dr. yoon Grad, reveals that doxycycline PEP is becoming less reliable, with evidence suggesting a decline in its protective effect.”We’re seeing a concerning trend,” explains Grad. “The bacteria are adapting, and the effectiveness of doxycycline is waning. While it still offers some protection, we need to be realistic about its limitations.”
Why Doxycycline PEP is a “Bridge” – and What Happens When the Bridge Weakens
Experts emphasize that doxycycline PEP isn’t a long-term solution, but rather a temporary measure - a “bridge” – until a more sustainable strategy, like a vaccine, becomes available.
“As I’ve been saying for ages and others are too, it really needs to be seen as a bridge to an effective vaccine for [gonorrhea],” says Jeanne Marrazzo, a leading STI expert and former director of the National Institute of Allergy and Infectious Diseases.
The concern is that relying too heavily on doxycycline PEP could accelerate the development of resistance,rendering it useless. While Marrazzo doesn’t believe it’s time to halt its use immediately, she stresses the need to acknowledge its possibly transient benefits.
The Importance of Surveillance – and a Past Setback
Monitoring the evolution of Neisseria gonorrhoeae, the bacteria that causes gonorrhea, is crucial for tracking resistance patterns and informing treatment guidelines. Though, this vital surveillance work was jeopardized when, in April 2025, the laboratory at the Centers for Disease control and Prevention (CDC) responsible for this type of analysis was unexpectedly closed under the Trump management.
“We won’t have the ability to do this type of analysis if we lose the resources that CDC has available for it,” warns Marrazzo. Fortunately, the decision to close the lab was later reversed, but the incident serves as a stark reminder of the fragility of public health infrastructure.Barbara Van Der Pol, a professor of medicine and public health at the University of alabama at Birmingham, underscores the ongoing need for vigilance.”Monitoring of Neisseria gonorrhoeae is an critically important public health need,” she states.
A Practice That’s Hard to Stop
Despite not being officially recommended, doxycycline PEP has gained meaningful traction within at-risk communities.A recent study published in Eurosurveillance surveyed over 1,600 men who have sex with men, transgender, and gender-diverse individuals in the Netherlands. The results revealed that 22% had used doxycycline PEP or PrEP (pre-exposure prophylaxis) informally, 15% were recent users, and a substantial 65% expressed a high intention to use it.
“I think it’s a hard genie to put back in the bottle,” admits Grad. “I don’t think we’re going to stop doxycycline PEP,and I think doxycycline PEP has good clinical indications. You want to try to reduce the rates of syphilis and chlamydia.”
Looking Ahead: The Urgent Need for a gonorrhea Vaccine
The evolving resistance of gonorrhea highlights the limitations of relying solely on antibiotics. The development of a gonorrhea vaccine is now considered a top priority by many public health experts.A accomplished vaccine would not only prevent new infections but also reduce the need for antibiotics,slowing the development of further resistance.